Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant. - Wikidata - awgldk - TriplyDB

Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant.

Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant.

http://www.wikidata.org/entity/Q33831941

about

Chk2 deficiency in Myc overexpressing lymphoma cells elicits a synergistic lethal response in combination with PARP inhibition Chk2 suppresses the oncogenic potential of DNA replication-associated DNA damage Checkpoint kinase 2 (Chk2) inhibits the activity of the Cdc45/MCM2-7/GINS (CMG) replicative helicase complex.Mice with the CHEK2*1100delC SNP are predisposed to cancer with a strong gender bias.Taking the time to make important decisions: the checkpoint effector kinases Chk1 and Chk2 and the DNA damage response.Cell cycle proteins as promising targets in cancer therapy Defective Mre11-dependent activation of Chk2 by ataxia telangiectasia mutated in colorectal carcinoma cells in response to replication-dependent DNA double strand breaks.Mammary tumor phenotypes in wild-type aging female FVB/N mice with pituitary prolactinomas.

P2860

Q28396027-9862BCC6-B284-4C2E-AD9F-DA338BD95D5B Q28511458-42D229C0-5F51-4B53-86E4-87CBF5F162B1 Q36170865-BDAC4518-1569-4A87-AD3E-4D43B936F171 Q37386101-68B5F2BA-85BA-4A88-9C20-BC261526EB4B Q37497709-F0CAE1C0-9210-40C7-83DF-6A4D017A616A Q37693690-530DB0EC-E2A2-4953-A946-118D8C937769 Q40244137-953E7A8E-70B2-45DB-9620-B2E599BE4773 Q44130924-3C244FBD-4556-4BA8-9E0F-C11E0ED41015

P2860

Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant.

http://www.wikidata.org/entity/Q33831941

description

2006 nî lūn-bûn

@nan

2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

name

Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant.

@ast

Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant.

@en

type

label

Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant.

@ast

Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant.

@en

prefLabel

Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant.

@ast

Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant.

@en

P1433

Q33831941-E2227A71-ED2F-428F-A8FA-A9B013068E98

P1476

Q33831941-CBE082E0-D6E9-420B-99B9-FB4A2C9D5121

P2093

Q33831941-06947641-7659-4C06-870F-1EEC18886CB7

Q33831941-37E662E1-6E74-4D83-A9C9-4749FD484289

Q33831941-3941700A-C427-4ED2-9658-F231E5B86F8F

Q33831941-6C515A20-3FF0-45BB-81F1-CD0EC12B8007

Q33831941-DE058BEF-75B3-48C6-ADB0-08B62C97F84D

Q33831941-F76EF9F1-80F2-4AA6-B81D-B25DB24784A8

P2860

Q33831941-01F2118F-4873-41EC-8B29-E8530C8D5F81

Q33831941-072380B9-1FAF-4B9A-A946-EEA18D1A1D01

Q33831941-1B095FD4-0F49-4DB0-A6CB-B9691CCFCF81

Q33831941-20E80641-5790-4D53-A552-3734455F8578

Q33831941-26D23B23-CB15-4497-A667-AD3DF7A5985F

Q33831941-356CE1ED-E586-4DF8-A4A9-E402C2F982C5

Q33831941-3A8B5AB2-E596-4CA8-84C2-B6599C1E7BC0

Q33831941-41C2E1E2-E178-4668-961D-AD9D0F27033F

Q33831941-48C1C7D6-17C4-41F0-BF95-7EF0DA1E3C1F

Q33831941-4AFF38EE-974C-4D18-A374-F16D772181B5

P304

Q33831941-C842948E-3F4C-4F5B-ABBC-7190914D63EC

P31

Q33831941-3A91A3EB-8B6F-4A94-AFC7-D64981E273AC

P356

Q33831941-8C56110A-5B87-4A87-BD8C-A5F8CD214C36

P407

Q33831941-2C0EA204-5D80-48E2-A545-FD8B660DADA8

P433

Q33831941-4BBC85EF-6995-4551-9609-DB8506ABC8CC

P478

Q33831941-4175A5EA-2D1C-4470-9392-2BEFD556BE9F

P577

Q33831941-8C33FE9F-9DB3-4FEE-A668-DBDF113763DB

P698

Q33831941-5DFFB46C-9DB1-4933-8055-C651D0735AB6

P932

Q33831941-D7B86B32-8022-4E11-A880-52BB0476F06C

P356

0008-5472.CAN-05-1237

P1433

Cancer Research

P1476

Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant.

@en

P2093

Daniel A Haber

http://www.w3.org/2001/XMLSchema#string

Emmett V Schmidt

http://www.w3.org/2001/XMLSchema#string

Eunice L Kwak

http://www.w3.org/2001/XMLSchema#string

Jianmin Zhang

http://www.w3.org/2001/XMLSchema#string

Robert D Cardiff

http://www.w3.org/2001/XMLSchema#string

Sang Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome

The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis

Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53

The DNA damage response: putting checkpoints in perspective

DNA damage-induced activation of p53 by the checkpoint kinase Chk2

hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response

DNA double-strand breaks: signaling, repair and the cancer connection

Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations

Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease.

CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies.

P304

1923-1928

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-05-1237

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P577

2006-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16488990

http://www.w3.org/2001/XMLSchema#string

P932

2865171

http://www.w3.org/2001/XMLSchema#string